Aptose Biosciences

Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

APTO's lead candidate, CG-806, is due for important updates in 4Q2020.

Aptose Biosciences: Validation Impending For This Targeted Oncology Player

SAN DIEGO and TORONTO, Aug.  06, 2020  (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, Ph.D., President and Chief Executive Officer; Gregory K. Chow, Executive Vice President and Chief Financial Officer; and Joti Marango, M.D., Ph.D, Senior Vice President and Chief Business Officer, will participate in the Canaccord Genuity 40th Annual Growth Conference being held in a virtual format from Tuesday, August 11th to Thursday, August 13th, 2020. 

Aptose Biosciences to Present at Canaccord Genuity 40th Annual Growth Conference

Aptose has recently raised more cash, and looks set for its foreseeable clinical trial needs.

Aptose: Boring Today, But Things Could Get Exciting Later This Year

Aptose Biosciences Inc. (APTO) CEO William Rice on Q2 2020 Results - Earnings Call Transcript

SAN DIEGO and TORONTO, July  21, 2020  (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended June 30, 2020, on Tuesday, August 4, 2020, after the close of the market.

Aptose to Release Second Quarter Ended June 30, 2020 Financial Results and Hold Conference Call on August 4, 2020

Why Aptose Biosciences Stock Sank Today

SAN DIEGO and TORONTO, July  15, 2020  (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS) today announced that it has commenced an underwritten public offering of its common shares (the “Offering”). In addition, Aptose intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the common shares offered in the Offering. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering. All of the common shares to be sold in the proposed offering will be sold by the Company.

Aptose Announces Proposed Public Offering of Common Shares

Oral FLT3/BTK inhibitor CG-806 expands development beyond B-cell malignancies to the treatment of AML

Aptose Announces FDA Allowance of IND for Phase 1a/b Study of CG-806 in Acute Myeloid Leukemia

Sarepta Therapeutics

Can the run for Sarepta Therapeutics, Viela Bio, and Aptose Biosciences continue?

3 Ultra-High-Growth Biopharma Stocks to Grab Now

Safety, tolerability and phospho-BTK inhibition at first three CG-806 dose levels in patients with CLL and other B-cell malignancies

Aptose Presents Early Phase 1a/b CG-806 Clinical Findings at the 25th Congress of the European Hematology Association

Aptose Biosciences' (APTO) CEO William Rice on Q1 2020 Results - Earnings Call Transcript

Data from patients at first two dose levels; Phase 1a/b study is ongoing Data from patients at first two dose levels; Phase 1a/b study is ongoing

Aptose Presents Preliminary Clinical Data on CG-806 at AACR Virtual Annual Meeting 2020

Aptose Riding Higher As The Street Starts Paying Attention

Aptose Biosciences Inc. (APTO) CEO William Rice on Q4 2019 Results - Earnings Call Transcript

Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Aptose (APTO) Stock?

Investing in this emerging cancer-focused biotech may just allow you to retire early.

Could This Cancer Drug Developer’s Stock Make You Rich?

SAN DIEGO and TORONTO, Dec.  19, 2019  (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced the closing of its previously announced underwritten public offering of 18,543,750 common shares (the “Offering”) at the public offering price of US$4.00 per share. The number of shares sold includes the full exercise by the underwriters of their option to purchase additional common shares in the Offering.  Gross proceeds from the Offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Aptose, are approximately US$74.2 million. 

Aptose Announces Closing of Public Offering of Common Shares

Investors excited about the biotech's prospects are taking the opportunity to buy on the dip following the announcement of a new stock offering.

Why Aptose Biosciences Shares Are Jumping Today

Promising preclinical data and the acquisition of another small biotech continued to generate enthusiasm among investors.

Why Aptose Biosciences Shares Jumped Today

SAN DIEGO and TORONTO, Dec.  09, 2019  (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the presentation of preclinical data for its first-in-class, FLT3/BTK inhibitor CG-806 at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, FL. The University of Texas MD Anderson Cancer Center researchers presented two posters elucidating CG-806’s mechanism of action in targeting chronic lymphcytic leukemia (CLL) cells and its inhibitory effect on ibrutinib-resistant mantle cell lymphoma (MCL) cells. 

Aptose Presents New Preclinical CG-806 Data at the 2019 ASH Annual Meeting

Aptose Management and KOL’s Discuss Early Clinical Observations with  CG-806 and APTO-253 Aptose Management and KOL’s Discuss Early Clinical Observations with  CG-806 and APTO-253

Aptose Presents Highlights From Corporate Event At ASH

SAN DIEGO and TORONTO, Dec.  04, 2019  (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the appointment of Rafael Bejar, M.D., Ph.D., to the position of Senior Vice President, Chief Medical Officer, effective January 1, 2020. In his role as a member of the executive leadership team, Dr. Bejar will oversee global clinical development and regulatory initiatives for Aptose, as well as other research activities.

Aptose Appoints Rafael Bejar, M.D., Ph.D., as Chief Medical Officer

SAN DIEGO and TORONTO, Dec.  02, 2019  (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate in the 31st Annual Piper Jaffray Healthcare Conference at the Lotte Palace Hotel in New York.  Aptose will be presenting and hosting 1x1 meetings.

Aptose to Present at 31st Annual Piper Jaffray Healthcare Conference

SAN DIEGO and TORONTO, Nov.  07, 2019  (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate in the 25th Annual International BIO-Europe Partnering Conference, being held November 11th -13th in Hamburg, Germany. Aptose will be presenting and hosting 1x1 meetings.

Aptose to Present at BIO-Europe Conference

Aptose Biosciences, Inc. (APTO) CEO William Rice on Q3 2019 Results - Earnings Call Transcript

News for Aptose Biosciences Stock (APTO)